Details

Autor(en) / Beteiligte

• Yu, Jin-Tai
• Xu, Wei
• Tan, Chen-Chen
• Andrieu, Sandrine
• Suckling, John
• Evangelou, Evangelos
• Pan, An
• Zhang, Can
• Jia, Jianping
• Feng, Lei
• Kua, Ee-Heok
• Wang, Yan-Jiang
• Wang, Hui-Fu
• Tan, Meng-Shan
• Li, Jie-Qiong
• Hou, Xiao-He
• Wan, Yu
• Tan, Lin
• Mok, Vincent
• Tan, Lan
• Dong, Qiang
• Touchon, Jacques
• Gauthier, Serge
• Aisen, Paul S
• Vellas, Bruno

Titel

Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials

Ist Teil von

• Journal of neurology, neurosurgery and psychiatry, 2020-11, Vol.91 (11), p.1201-1209

Ort / Verlag

England: BMJ Publishing Group LTD

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• BackgroundEvidence on preventing Alzheimer’s disease (AD) is challenging to interpret due to varying study designs with heterogeneous endpoints and credibility. We completed a systematic review and meta-analysis of current evidence with prospective designs to propose evidence-based suggestions on AD prevention.MethodsElectronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OPSs) and randomised controlled trials (RCTs) were included. The multivariable-adjusted effect estimates were pooled by random-effects models, with credibility assessment according to its risk of bias, inconsistency and imprecision. Levels of evidence and classes of suggestions were summarised.ResultsA total of 44 676 reports were identified, and 243 OPSs and 153 RCTs were eligible for analysis after exclusion based on pre-decided criteria, from which 104 modifiable factors and 11 interventions were included in the meta-analyses. Twenty-one suggestions are proposed based on the consolidated evidence, with Class I suggestions targeting 19 factors: 10 with Level A strong evidence (education, cognitive activity, high body mass index in latelife, hyperhomocysteinaemia, depression, stress, diabetes, head trauma, hypertension in midlife and orthostatic hypotension) and 9 with Level B weaker evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C). In contrast, two interventions are not recommended: oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B).InterpretationEvidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.